Search Results - Tse‐Chieh Teh
- Showing 1 - 7 results of 7
-
1
Bortezomib-based antibody depletion for refractory autoimmune hematological diseases by Sumita Ratnasingam, Patricia Walker, Huy Tran, Zane Kaplan, James D. McFadyen, Huyen Tran, Tse-Chieh Teh, Shaun Fleming, John Catalano, Sanjeev Chunilal, Anna Johnston, Stephen Opat, Jake Shortt
Published 2016Artigo -
2
Final Analysis of the Phase 1b Chemotherapy And Venetoclax in Elderly Acute Myeloid Leukaemia Trial (CAVEAT) by Chong Chyn Chua, Sun Loo, Chun Yew Fong, Stephen B. Ting, Ing Soo Tiong, Shaun A Fleming, Natasha S. Anstee, Adam Ivey, Michael Ashby, Tse-Chieh Teh, John Reynolds, Andrew W. Roberts, Andrew H. Wei
Published 2025Artigo -
3
Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML by Sewa Rijal, Shaun Fleming, Nik Cummings, Natalie K. Rynkiewicz, Lisa M. Ooms, Nhu-Y. N. Nguyen, Tse‐Chieh Teh, Sharon Avery, Julie F. McManus, Anthony T. Papenfuss, Catriona McLean, Mark A. Guthridge, Christina A. Mitchell, Andrew H. Wei
Published 2015Artigo -
4
Venetoclax induces rapid elimination of <i>NPM1</i> mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia by Ing Soo Tiong, Richard Dillon, Adam Ivey, Tse‐Chieh Teh, Phillip Nguyen, Nicholas J. Cummings, David Taussig, Annie‐Louise Latif, Nicola Potter, Manohursingh Runglall, Nigel H. Russell, Kavita Raj, Anthony P. Schwarer, Chun Yew Fong, Andrew Grigg, Andrew H. Wei
Published 2020Artigo -
5
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC) by Ing Soo Tiong, Devendra Hiwase, Emad Uddin Abro, Ashish Bajel, Emma Palfreyman, Ashanka Beligaswatte, John Reynolds, Natasha S. Anstee, Tamia Nguyen, Sun Loo, Chong Chyn Chua, Michael Ashby, Kaitlyn Wiltshire, Shaun Fleming, Chun Yew Fong, Tse‐Chieh Teh, Piers Blombery, Richard Dillon, Adam Ivey, Andrew H. Wei
Published 2024Artigo -
6
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia by Donia M. Moujalled, Giovanna Pomilio, Corina Ghiurau, Adam Ivey, Jessica M. Salmon, Sewa Rijal, Sarah MacRaild, Lan Zhang, Tse-Chieh Teh, Ing Soo Tiong, Ping Lan, Maïa Chanrion, Audrey Clapéron, Francesca Rocchetti, Adrien Zichi, Laurence Kraus‐Berthier, Youzhen Wang, Ensar Halilovic, Erick J. Morris, Frédéric Colland, David Segal, David C.S. Huang, Andrew W. Roberts, Ana Leticia Maragno, Guillaume Lessène, Olivier Geneste, Andrew H. Wei
Published 2018Artigo -
7
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription by Danièl Thomas, Jason A. Powell, François Vergez, David Segal, Nhu-Y. N. Nguyen, Adele Baker, Tse‐Chieh Teh, Emma F. Barry, Jean‐Emmanuel Sarry, Erwin M. Lee, Tracy L. Nero, Anissa M. Jabbour, Giovanna Pomilio, Benjamin D. Green, Stéphane Manenti, Stefan Glaser, Michael W. Parker, Angel F. López, Paul G. Ekert, Richard B. Lock, David C.S. Huang, Susan K. Nilsson, Christian Récher, Andrew H. Wei, Mark A. Guthridge
Published 2013Artigo
Search Tools:
Related Subjects
Medicine
Leukemia
Oncology
Biochemistry
Biology
Chronic lymphocytic leukemia
Internal medicine
Myeloid leukemia
Venetoclax
Cancer research
Chemistry
Chemotherapy
Cytarabine
Immunology
Myeloid
Azacitidine
Cyclophosphamide
Cytotoxic T cell
DNA methylation
Fludarabine
Gastroenterology
Gene
Gene expression
Genetics
In vitro
Minimal residual disease
Antibody
Apoptosis
Astrobiology
Bone marrow